Open AccessBook
Myasthenia Gravis
Huub Oosterhuis
- 01 Jan 1997
2.4K
About: The article was published on 01 Jan 1997. and is currently open access. The article focuses on the topics: Myasthenia gravis & Ocular myasthenia.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Frequency and clinical features of treatment-refractory myasthenia gravis.
Jakob Rath,Ines Brunner,Matthias Tomschik,Gudrun Zulehner,E. Hilger,Martin Krenn,Anna Paul,Hakan Cetin,Fritz Zimprich +8 more
TL;DR: A small subgroup of patients with generalized myasthenia gravis do not respond sufficiently to standard therapies and are at higher risk for a refractory course, highlighting an unmet need for new treatment options.
Anti-thyroglobulin autoantibodies in sera from patients with chronic thyroiditis and from healthy subjects: differences in cross-reactivity with thyroid peroxidase.
Naokazu Naito,K. Saito,Toichiro Hosoya,Osamu Tarutani,Shigeki Sakata,T. Nishikawa,Hiroo Niimi,Hiroshi Nakajima,Y. Kohno +8 more
TL;DR: It can be concluded that anti‐Tg antibodies from healthy subjects differ from those of patients with chronic thyroiditis with respect to TPO binding, probably due to difference in fine specificities of these anti‐ Tg antibodies.
34
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies
TL;DR: In MG with antibodies to MuSK, ocular manifestations were as frequent as in other disease subtypes, and Symmetrical ophthalmoparesis with conjugated gaze limitation was rather common and associated with low functional disability.
34
Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis
TL;DR: Tacrolimus is an important option for treatment of MG; however, careful management is needed for long-term treatment with this drug, as 5 of the 9 patients experienced exacerbation of symptoms and transient increases in PSL dose during the 5-year period.
33
Patent
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
Luke W. Ashcraft,Gustave Bergnes,Scott Collibee,Chihyuan Chuang,Jeff Gardina,Morgan Bradley P,Alex Muci,Xiangping Qian,Antonio Romero,Jeffrey Warrington,Zhe Yang +10 more
- 22 Apr 2011
TL;DR: In this paper, compounds of Formula I: Formula I or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein.
33